Janssen Strengthens Prostate Cancer Pipeline with Aduro BioTech Collaboration
By Heather Cartwright
Pharma Deals Review: Vol 2014 Issue 6 (Table of Contents)
Published: 21 Jun-2014
DOI: 10.3833/pdr.v2014.i6.2044 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Johnson & Johnson’s Janssen Biotech has licensed global rights to certain prostate cancer immunotherapies developed by Aduro BioTech based on its LADD platform, which uses live-attenuated double-deleted Listeria monocytogenes strains...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS